Anti-inflammatory and pro-proliferative effects of fasudil in human trisomy 21 neural progenitor cells

This study demonstrates that the ROCK inhibitor fasudil exhibits beneficial anti-inflammatory and pro-proliferative effects on human trisomy 21 neural progenitor cells, suggesting its potential as a candidate prenatal pharmacotherapy for Down syndrome.

The Gist

The Big Picture: Fixing a "Glitch" Before It Starts

Imagine the human brain is like a massive, complex construction site. For most people (called "euploid" in the study), the blueprints are perfect, and the builders (cells) follow the instructions exactly.

For people with Down syndrome (Trisomy 21), there is an extra copy of a specific instruction manual (Chromosome 21). It's like having three copies of the same page in a book instead of two. This doesn't just add a little bit of extra information; it throws the whole construction site into chaos. The builders get confused, work slower, and the building (the brain) doesn't grow quite right.

The big problem? By the time a child is born and shows signs of learning difficulties, the "construction" is already mostly finished. The researchers believe that to truly help, we need to fix the blueprints and the builders while the baby is still in the womb.

The Experiment: Testing 24 "Medicinal Tools"

The scientists set up a laboratory "construction site" using human stem cells. They grew two types of teams:

1. Team Normal: Cells with the standard two copies of the chromosome.
2. Team Down Syndrome: Cells with the extra third copy.

They wanted to see if they could find a chemical "tool" that could calm down the chaos in Team Down Syndrome and help them build a better brain. They tested 24 different candidate molecules (drugs or natural compounds).

Think of this like a mechanic trying to fix a car with a weird engine noise. They try 24 different fluids and parts to see which one actually makes the engine run smoothly without breaking anything else.

The Star Player: Fasudil

Out of the 24 tools tested, one stood out as the MVP: a drug called Fasudil.

Here is what Fasudil did, explained through three simple analogies:

1. The "Speed Boost" Analogy (Proliferation)

In the Down syndrome construction site, the builders were moving very slowly. They were tired and didn't want to multiply.

• Without Fasudil: The builders were sluggish.
• With Fasudil: It was like giving them a fresh cup of coffee and a pep talk. The builders started working faster and multiplying more quickly. Crucially, this speed boost was much stronger for the Down syndrome team than for the normal team. It helped the slow team catch up.

2. The "Fire Extinguisher" Analogy (Inflammation)

The Down syndrome brain is often in a state of low-level "fire" or inflammation. It's like a construction site where the workers are constantly arguing and shouting, which stops them from building.

• The Problem: The cells were shouting (inflammatory genes) and sending out smoke signals (inflammatory markers).
• The Fix: Fasudil acted like a powerful fire extinguisher. It calmed the workers down, stopped the shouting, and put out the smoke. When they tested this on immune cells (the brain's security guards), Fasudil stopped them from overreacting to stress.

3. The "Tuning Fork" Analogy (Gene Expression)

Imagine the cells are a choir. In the Down syndrome group, many singers are hitting the wrong notes (genes are turned on or off incorrectly).

• The Result: When Fasudil was added, it didn't just make them louder; it helped them hit the right notes again. The researchers found that Fasudil "corrected" thousands of these wrong notes, bringing the choir closer to the harmony of the normal group.

The Surprise: One Size Does Not Fit All

One of the most important discoveries in this paper is that what works for a normal cell doesn't always work for a Down syndrome cell.

The researchers tested the drugs on both teams. They found that the Down syndrome cells reacted very differently than the normal cells.

• The Lesson: You can't just look at how a drug works on a "normal" person and assume it will work the same way on someone with Down syndrome. The extra chromosome changes the rules of the game. This is why many drugs that worked in mice (which aren't perfect models for humans) failed in human trials. Using actual human cells with the extra chromosome was key to finding the right tool.

What About the Other Drugs?

They tested other popular candidates, like EGCG (found in green tea) and Apigenin.

• The Green Tea Twist: Many parents give green tea supplements to children with Down syndrome hoping it helps. However, in this specific lab test, the green tea compound (EGCG) actually made the gene expression worse for the Down syndrome cells. It was like trying to fix a leaky pipe with a hammer—it might work for a different problem, but here it made things messier.
• Isoxsuprine: This drug showed some promise in calming inflammation in immune cells, but it didn't do much for the growth of the brain cells themselves.

The Bottom Line

This study is a major step forward because it used human cells to find a treatment that targets the specific problems of Down syndrome.

Fasudil looks very promising because it does three things at once:

1. It speeds up the growth of brain cells.
2. It calms down the inflammation.
3. It fixes the genetic "typos" caused by the extra chromosome.

The Future:
Fasudil is already used in Japan to treat brain blood vessel issues, so we know it's generally safe for adults. The next step is to see if it can be safely given to pregnant women to help their babies with Down syndrome develop better brains before they are even born.

In short: The researchers found a "magic key" (Fasudil) that fits the specific lock of Down syndrome, helping the brain build itself correctly before the baby is born.

Technical Summary

1. Problem Statement

Down syndrome (DS), caused by trisomy 21 (T21), is the most common genetic cause of intellectual disability. Atypical brain development, including structural alterations and regional hypoplasia, is evident prenatally, suggesting that therapeutic interventions must occur during fetal development to be effective. However, translating preclinical findings from mouse models (e.g., Ts65Dn, Dp(16)1Yey) to humans has been challenging due to:

• Incomplete modeling: Mouse models are only partially trisomic for human chromosome 21 orthologs and contain non-syntenic aneuploid regions.
• Species differences: Murine and human neurodevelopment differ significantly, leading to inconsistent clinical trial outcomes for previously promising candidates (e.g., EGCG, fluoxetine).
• Lack of human models: There is a scarcity of human fetal brain tissue for study.

The study aims to identify safe and effective prenatal pharmacotherapies for DS using a human in vitro model that fully recapitulates the T21 genotype.

2. Methodology

The researchers utilized a multi-step pipeline combining transcriptomics, high-throughput screening, and molecular biology:

• Cell Model: The study used a panel of age- and sex-matched human induced pluripotent stem cells (iPSCs) derived from unrelated euploid (Eup) individuals and individuals with T21. These were differentiated into Neural Progenitor Cells (NPCs). The T21 NPCs were confirmed to exhibit reduced proliferation, increased oxidative stress, and transcriptomic disruption.
• Candidate Selection:
  • Transcriptomic Approach: Differentially expressed genes (DEGs) from T21 NPCs were used to query the Library of Integrated Network-Based Cellular Signatures (LINCS). This identified 165 small molecules predicted to reverse the T21 gene signature.
  • Screening: 17 molecules from the LINCS list (selected for lack of teratogenicity) and 7 previously published candidates (e.g., apigenin, EGCG, fasudil) were selected for testing.
• Proliferation Assays:
  • NPCs were transduced with a nuclear-restricted fluorescent vector (Nuclight Red) for automated live-cell imaging.
  • Cells were treated with candidates at varying concentrations in 384-well and 6-well plates.
  • Growth curves were generated over 120 hours to calculate doubling times (DT).
• Inflammation Models:
  • RAW 264.7 (Mouse Macrophages): Treated with LPS to induce inflammation, then challenged with candidates to measure nitrite, TNF-α, and IL-6 levels.
  • IMG (Immortalized Mouse Microglia): Used to validate anti-inflammatory effects and assess Nuclear Factor kappa B (NF-κB) nuclear translocation via immunofluorescence.
• Transcriptomic Analysis (RNA-Seq):
  • Bulk RNA-Seq was performed on Eup and T21 NPCs treated with the top candidates (Fasudil, EGCG, Apigenin, Isoxsuprine, Sphingosine).
  • Differential gene expression (DEG) analysis compared treated vs. untreated cells and T21 vs. Eup cells.
  • Pathway enrichment analysis (IPA, Metascape, MSigDB) was used to identify biological processes affected.

3. Key Contributions

• Validation of Human NPC Models: Demonstrated that human T21 NPCs are a superior in vitro model for screening prenatal therapeutics compared to mouse models, revealing genotype-specific transcriptomic responses that mouse models might miss.
• Identification of Fasudil: Identified the Rho-associated coiled-coil kinase (ROCK) inhibitor fasudil as a lead candidate that simultaneously addresses multiple T21-associated defects (proliferation and inflammation).
• Genotype-Specific Drug Response: Provided evidence that Eup and T21 cells respond differently to the same pharmacological agents, highlighting the necessity of testing drugs directly on T21 cells rather than inferring efficacy from euploid controls.
• Mechanistic Insight: Linked ROCK inhibition to the restoration of Sonic Hedgehog (SHH) signaling and the suppression of interferon/inflammatory pathways in T21 cells.

4. Key Results

A. Proliferation Effects

• Fasudil: Consistently increased proliferation and reduced doubling time in T21 NPCs. The effect was genotype-dependent; T21 cells showed a significantly greater reduction in doubling time (-8.92 hrs) compared to Eup cells (-3.02 hrs). The effect was most pronounced in slower-growing T21 lines.
• Other Candidates: EGCG, Apigenin, Isoxsuprine, and Sphingosine showed inconsistent or negligible effects on T21 NPC proliferation. Some (e.g., Sphingosine) actually slowed growth in Eup lines.

B. Anti-Inflammatory Effects

• Fasudil, Apigenin, Isoxsuprine: All three significantly reduced LPS-induced inflammatory markers (nitrite, TNF-α, IL-6) in RAW 264.7 cells.
• Mechanism: In IMG microglia, Fasudil and Isoxsuprine reduced nuclear translocation of NF-κB, a key driver of inflammation. Fasudil showed no toxicity at effective anti-inflammatory concentrations.
• Contrast: EGCG and Sphingosine showed pro-inflammatory or toxic effects in these models.

C. Transcriptomic Correction (RNA-Seq)

• Fasudil in T21: Treatment with Fasudil (8 µM) induced 1,649 DEGs in T21 NPCs. Crucially, 83.5% of the overlapping DEGs between T21 baseline dysregulation and Fasudil treatment showed correction (expression moved toward Eup levels).
  • Downregulated: Inflammatory pathways (Interferon α/γ, TNF-α/NF-κB signaling, Hypoxia, CGAS-STING).
  • Upregulated: Cell cycle, chromosome replication, and Sonic Hedgehog (SHH) signaling pathways.
• Fasudil in Eup: Eup NPCs showed minimal transcriptomic changes (only 172 DEGs) compared to T21, indicating Fasudil specifically targets T21-associated dysregulation.
• Other Candidates:
  • EGCG & Sphingosine: Induced gene expression changes that largely worsened T21-associated dysregulation (e.g., upregulating immune pathways and extracellular matrix organization in a manner consistent with T21 pathology).
  • Apigenin & Isoxsuprine: Showed minimal transcriptional impact on T21 NPCs.

5. Significance and Conclusion

• Therapeutic Potential: Fasudil emerges as a strong candidate for prenatal pharmacotherapy for DS. It addresses the "double hit" of T21: reduced neurogenesis (via proliferation enhancement) and chronic neuroinflammation (via ROCK/NF-κB inhibition).
• Clinical Relevance: Fasudil is already FDA-approved (in Japan) for cerebral vasospasm and is currently in clinical trials for neurodegenerative diseases (ALS, Parkinson's), suggesting a favorable safety profile. The study supports the feasibility of prenatal administration during later gestational stages.
• Paradigm Shift: The study underscores that Euploid cells cannot predict therapeutic responses in T21 cells. The distinct transcriptomic responses observed suggest that drug discovery for aneuploidy syndromes must utilize trisomic cell models to avoid false negatives or positives derived from euploid screens.
• Future Directions: The authors recommend further in vivo validation in humanized models and clinical trials focusing on prenatal administration of Fasudil to improve neurodevelopmental outcomes in individuals with Down syndrome.